C.Q.Pharmaceutical Holding Co.Ltd(000950)
Annual report for 2021
April 2022
Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Yuan Quan, the person in charge of the company, Qiu Tian, the person in charge of accounting, and Yin Yi, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.
All directors have attended the meeting of the board of directors to consider this report.
The company may have risks in industry competition, operation and management, market and national policies. Please pay attention to the investment risks.
The company’s profit distribution plan reviewed and approved by the board of directors is: take 174336733700 as the base, distribute cash dividend of 0.65 yuan (including tax) to all shareholders for every 10 shares, send bonus shares of 0 share (including tax), and do not use the accumulation fund to increase the share capital.
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance Section V environmental and social responsibility Section VI important matters Section VII changes in shares and shareholders 98 Section VIII preferred shares 105 section IX relevant information of bonds 106 section x financial reporting one hundred and seven
Directory of documents for future reference
(I) financial statements signed and sealed by the person in charge of the company, the person in charge of accounting work and the person in charge of accounting organization (Accounting Supervisor). (II) the original of the audit report sealed by the accounting firm and signed and sealed by the certified public accountant. (III) originals of all company documents and announcements publicly disclosed on the website designated by the CSRC during the reporting period. (IV) the original copy of the 2021 annual report signed by the chairman. (V) place where the above documents for future reference are prepared: Securities Department of the company (Office of the board of directors).
interpretation
Explanatory item refers to the explanatory content
Listed company, company, the company, C.Q.Pharmaceutical Holding Co.Ltd(000950) refers to C.Q.Pharmaceutical Holding Co.Ltd(000950) , the former Chongqing Jianfeng Chemical Co., Ltd
Chongqing pharmaceutical Co., Ltd. refers to Chongqing pharmaceutical (Group) Co., Ltd
Chemical medicine group refers to Chongqing chemical medicine holding (Group) company
Jianfeng group refers to Chongqing Jianfeng Industry Group Co., Ltd., the former Jianfeng Chemical Plant of China nuclear industry
China Meheco Group Co.Ltd(600056) refers to China Meheco Group Co.Ltd(600056)
Boyi fund refers to Chongqing Boyi Xintian equity investment fund partnership (limited partnership)
Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) means Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196)
Heavy salt group refers to Chongqing salt industry (Group) Co., Ltd
Chemical medicine finance company refers to Chongqing chemical medicine holding group finance Co., Ltd
Major asset restructuring and reorganization refer to the trading behavior of the company’s major asset sales, issuance of shares, purchase of assets and related party transactions in 2017
Lixin and Lixin certified public accountants refer to Lixin Certified Public Accountants (special general partnership)
Municipal SASAC and Chongqing SASAC refer to Chongqing state owned assets supervision and Administration Commission
Chongqing pharmaceutical Tianjin refers to Chongqing pharmaceutical group (Tianjin) Pharmaceutical Commercial Co., Ltd., the former Tianjin Tasly Pharmaceutical Group Co.Ltd(600535) Pharmaceutical Marketing Group Co., Ltd
Inner Mongolia Tianhe refers to Chongqing pharmaceutical group Inner Mongolia Tianhe Pharmaceutical Co., Ltd., the former Inner Mongolia Tianhe Pharmaceutical Co., Ltd
Chongyao Changsheng refers to Chongqing pharmaceutical group Changsheng Pharmaceutical Co., Ltd., formerly Chongqing Changsheng Pharmaceutical Co., Ltd
Heavy drug Hangzhou refers to Chongqing Pharmaceutical Group Hangzhou Pharmaceutical Co., Ltd., formerly Zhejiang Astro Boy Pharmaceutical Co., Ltd
Asia-Potash International Investment (Guangzhou) Co.Ltd(000893) , Dongling international refers to Asia-Potash International Investment (Guangzhou) Co.Ltd(000893) , the former Guangzhou Dongling International Investment Co., Ltd
Chengdu Hechuang Pharmaceutical Group Co., Ltd; Chengdu Tongde Pharmaceutical Co., Ltd; Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Pharmaceutical Group Co., Ltd; Guilin Nanyao Co., Ltd; Huang Wen Maoye Commercial Co.Ltd(600828) Co., Ltd
Company; Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd; Shenzhen Maoye Group Co., Ltd Sichuan Languang Development Co.Ltd(600466) ; Chongqing Taiji Industry (Group) Co.Ltd(600129) Chongqing TongJunGe Pharmaceutical Co., Ltd. refers to 22 shareholders including Gonghua medical group; Tianjin Tianshi Jianfa biotechnology development partnership (limited partnership); Wang Jian; Wu Zhengzhong; Southwest Pharmaceutical Co., Ltd; Xiamen cod liver oil factory; Yang Wenbin; Chongqing Boyi Xintian Equity Investment Co., Ltd
Capital fund partnership (limited partnership); Chongqing chemical medicine holding (Group) Company; Chongqing railway self owned vehicle Co., Ltd; Chongqing hospital of traditional Chinese medicine; Chongqing Taiji Medicinal Plant Resources Development Co., Ltd; Chongqing strategic emerging industry pharmaceutical special equity investment fund partnership (limited partnership)
Commercial distribution refers to the sale of purchased drugs and medical devices by the company as a distributor of drugs and medical devices
To other pharmaceutical commercial enterprises
Hospital net sales refers to sales to medical and health institutions at or above the county level (Level II and III)
Self operated retail refers to the sales of medical and health institutions, social pharmacies and monomer pharmacies below the secondary / district / county level
Terminal distribution refers to the sales of medical institutions rated as grade I and below, and distinguish whether the sales target is chain clinics or not
Supply chain value-added service refers to customized professional, standardized and personalized drug supply extension service solutions for customers on the basis of comprehensive evaluation of customers’ actual situation and objective needs
Centralized procurement refers to the centralized procurement of drugs, which refers to the procurement method in which public medical institutions purchase the required drugs in a certain way (such as bidding) through the centralized procurement organization of drugs
It refers to 11 pilot areas, including 4 municipalities directly under the Central Government: Beijing, Shanghai, Tianjin and Chongqing; 7 sub 4 + 7 provincial cities: Shenyang, Dalian, Guangzhou, Shenzhen, Xiamen, Chengdu and Xi’an
On November 15, 2018, the joint procurement office of volume procurement, composed of representatives from 11 pilot areas represented by Shanghai, issued the document on centralized drug procurement in 4 + 7 cities.
It stipulates that “the catalogue of generic drugs approved by the new registration classification of chemical drugs shall be determined by the joint procurement meeting and consulting experts to determine the procurement varieties (specified specifications) and agreed procurement quantities”
A brand-new logistics service mode of hospital drugs, consumables and logistics materials, relying on modern information technology, to establish a complete set of hospital drugs, consumables and logistics materials SPD project logistics supply system; Break through the information transmission barrier of hospitals and commercial enterprises to ensure the timely supply of hospital materials; Optimize the logistics management process in the hospital, and realize the safety, efficiency and traceability of hospital material supply through information, intelligent and professional operation
The drug marketing license holder system usually refers to the drug R & D institutions with drug technology, the Department MAH system refers to the researchers, drug manufacturers and other entities who apply for drug marketing license and obtain the approval document of drug marketing license, And bear the main responsibility for drug quality in its whole life cycle
DTP prescription drug service refers to the service that DTP pharmacy provides patients with drug delivery, medication consultation and other services after patients get prescriptions in the hospital
ERP refers to the abbreviation of enterprise resource planning
WMS refers to the abbreviation of warehouse management system
CRM refers to customer relationship management
